Marseille, France, June 14, 2021 (GLOBE NEWSWIRE) – In accordance with articles L. 233-8 II of the French Commercial Code and 223-16 of the general regulations of the Autorité des marchés financiers (the “ AMF Innate Pharma SA Society “- Euronext Paris: FR0010331421 – IPH; Nasdaq: IPHA) publishes the number of shares making up its share capital as well as the number of associated voting rights as of June 1, 2021:
|Number of shares making up the capital:
||79,027,540 ordinary shares
||6,796 Preference Shares 2016
7,581 Preference Shares 2017
|Number of theoretical voting rights (1):
Number of exercisable voting rights (2):
|79 822 040
79 803 465
(1) The number of theoretical voting rights (or “gross” voting rights) is used as a basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all the shares to which voting rights are attached, including shares deprived of voting rights. The number of theoretical voting rights includes the voting rights attached to AGAP 2016, i.e. 130 voting rights per AGAP 2016-1 and 111 voting rights per AGAP 2016-2.
(2) The number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the treasury shares held by the Company, deprived of voting rights. It is communicated for the proper information of the public, in accordance with the AMF recommendation of July 17, 2007.
About Innate Pharma:
Innate Pharma SA is a clinical-stage biotechnology company specializing in immuno-oncology and dedicated to improving cancer treatment using innovative therapeutic antibodies exploiting the immune system.
Innate Pharma’s large antibody portfolio includes several potentially “first-in-class” candidates at the clinical and preclinical stages in cancers where the medical need is important.
Innate Pharma is a pioneer in understanding the biology of NK cells and has developed its expertise in the tumor microenvironment and tumor antigens, as well as in antibody engineering. Its innovative approach has enabled it to build a diversified proprietary portfolio and forge alliances with leading biopharmaceutical companies such as Bristol-Myers Squibb, Novo Nordisk A / S or Sanofi as well as a multi-product partnership with AstraZeneca.
Based in Marseille, with a subsidiary in Rockville (Maryland, United States), Innate Pharma is listed on Euronext Paris and on Nasdaq in the United States.
Find Innate Pharma on www.innate-pharma.com.
Useful information :
Euronext : IPH Nasdaq : IPHA
Warning regarding forward-looking information and risk factors:
This press release contains forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain terms, including “believe”, “potential”, “expect” and “will” and other similar expressions, are intended to identify forward-looking statements. Although the Company considers that its projections are based on reasonable assumptions, these forward-looking statements may be called into question by a number of risks and uncertainties, which could give rise to results materially different from those anticipated. These hazards and uncertainties include in particular the uncertainties inherent in research and development, including those relating to safety, progress and results of clinical trials and preclinical studies in progress or planned, reviews and authorizations of regulatory authorities concerning the Company’s product candidates, the Company’s commercial efforts, the Company’s ability to continue to raise funds for its development and the overall impact of the COVID-19 pandemic on health systems and operations , the financial situation and the results of the Company. For additional considerations in terms of risks and uncertainties that could cause the actual results, financial situation, performance and success of the Company to differ, please refer to the “Risk Factors” section of the Universal Registration Document. filed with the Autorité des marchés financiers (AMF), available on the websites of Innate Pharma (www.innate-pharma.com) and the AMF (www.amf-france.org), and the documents and public reports filed with the United States Securities and Exchange Commission (SEC), including the annual report on “Form 20-F” for the year ended December 31, 2020 and subsequent documents and reports filed with the AMF or SEC, or otherwise made public, by the Company.
This press release, and the information it contains, does not constitute an offer to sell or subscribe, nor the solicitation of an order to buy or subscribe, shares of Innate Pharma in any country.
For any further information, please contact: